Melasma Treatment Through the Decades: What Has Changed and What Works Now

What Melasma Actually Is and Why Women Bear the Burden

Melasma is a common, acquired disorder of excess melanin deposition that appears as symmetrical brown or gray-brown patches on sun-exposed skin, most often the face. It is not dangerous, but it is persistent and deeply affects quality of life.

Women carry an outsized share of this condition. Studies consistently place the female-to-male ratio at approximately 9:1, and the burden is highest among women with Fitzpatrick skin types III through VI, including those of Latin American, South Asian, Southeast Asian, Middle Eastern, and African descent. Prevalence estimates in high-risk populations range from 8.8% to as high as 40% depending on geography and UV exposure.

Three overlapping drivers explain why melasma is so female-dominant: ultraviolet radiation, genetic susceptibility, and female sex hormones. Estrogen and progesterone both stimulate melanocyte-stimulating hormone (MSH) receptors in skin, and melanocytes in melasma lesions overexpress estrogen receptor-alpha compared with unaffected adjacent skin. This hormonal-skin axis is the reason melasma tracks so closely with oral contraceptive use, pregnancy, fertility treatments, and hormone therapy in perimenopause and menopause.

Understanding the history of treatment means understanding this biology, because every decade of therapeutics has essentially tried to interrupt a different point in that same pathway.

Before the 20th Century: Caustics, Mercury, and the First Observations

Before modern dermatology existed, women with pronounced facial pigmentation had limited and genuinely dangerous options.

Mercury-Based Preparations

Mercury compounds, particularly ammoniated mercury (mercury chloride), were used topically for centuries and remained in commercial skin-lightening products well into the 1970s in some markets. Mercury inhibits the enzyme tyrosinase, which catalyzes a key step in melanin synthesis. It works, in a narrow sense. The harms are severe: systemic mercury absorption through intact skin causes nephrotoxicity, neurotoxicity, and endocrine disruption. Pregnant women using mercury-containing creams risked fetal exposure. The FDA formally banned mercury from over-the-counter skin-lightening products in 1973, though unregulated imported products continue to appear in global markets.

Carbolic Acid and Early Chemical Peels

Phenol (carbolic acid) was applied to hyperpigmented skin from at least the late 19th century onward. Practical results were inconsistent, and the risk of systemic phenol toxicity and permanent depigmentation made it unsuitable for routine use. These early observations did, however, establish two principles that still guide treatment: chemical interruption of melanin synthesis is possible, and the risk-benefit calculation in pigmentation treatment is always significant.

The Mid-20th Century: Hydroquinone and the Science of Tyrosinase Inhibition

The modern therapeutic era for melasma begins with hydroquinone.

Hydroquinone Enters the Picture

Hydroquinone (HQ) was identified as a depigmenting agent in 1936 when rubber factory workers exposed to hydroquinone-containing antioxidants developed occupational leukoderma. By the 1950s and 1960s, dermatologists began applying it intentionally to hyperpigmented skin. HQ works by inhibiting tyrosinase, the rate-limiting enzyme in the conversion of tyrosine to melanin, and by a secondary mechanism that reduces melanocyte viability at higher concentrations.

The FDA classified topical HQ 2% as an over-the-counter (OTC) drug and 4% as prescription. For decades, 4% HQ monotherapy was the de facto first-line treatment for melasma in the United States and across most of the world.

Limitations Recognized Early

Monotherapy results were modest. A 1994 clinical review published in the Journal of the American Academy of Dermatology documented a significant number of women experiencing rebound hyperpigmentation after stopping HQ, particularly those who remained on oral contraceptives or continued unprotected sun exposure. HQ also carries a risk of ochronosis (a paradoxical bluish-black discoloration) with prolonged use at high concentrations, seen more commonly in African and African American patients.

The FDA's 2006 proposed rule to remove HQ from the OTC monograph due to concerns about carcinogenicity (based on rodent data at suprapharmacologic doses) created significant regulatory uncertainty. As of 2025, prescription 4% HQ remains available in the United States, though the debate prompted acceleration of research into HQ alternatives.

The 1970s and 1980s: Tretinoin, Combination Strategies, and Sunscreen Science

Two parallel advances transformed melasma management in this period.

Tretinoin Joins the Toolkit

Tretinoin (all-trans retinoic acid), already established in acne treatment after Albert Kligman's foundational work at the University of Pennsylvania, was found to independently reduce melanin synthesis, accelerate epidermal turnover, and improve penetration of co-applied agents. Studies in the 1980s and 1990s demonstrated that tretinoin 0.1% cream produced statistically significant lightening of melasma over 40 weeks compared with vehicle. Tretinoin alone is slower than HQ alone, but the combination proved synergistic.

The Kligman-Willis Formula and Its Evolution

Dermatologist Albert Kligman and colleague Thomas Willis described a combination of HQ, tretinoin, and a topical corticosteroid in the 1970s. This formulation, later commercialized as Tri-Luma (HQ 4% / tretinoin 0.05% / fluocinolone acetonide 0.01%), became the only FDA-approved combination product specifically indicated for melasma. A key multicenter randomized controlled trial published in 2002 showed that this triple combination cream produced complete clearing or near-complete clearing in 26.1% of patients at 8 weeks, significantly outperforming any two-component combination.

Sunscreen as a Treatment, Not Just Prevention

The 1980s saw the first controlled data demonstrating that daily broad-spectrum sunscreen is not optional maintenance but an active therapeutic component. Without it, relapse rates approach 100% within 6 to 12 months of stopping any depigmenting agent. SPF 30 to 50 with UVA coverage (PPD rating or broad-spectrum designation) is now a required component of every evidence-based melasma regimen per the American Academy of Dermatology.

The 1990s and 2000s: Alternatives to Hydroquinone and the First Device Era

Regulatory pressure on HQ and growing demand from patients with deeper skin tones drove active research into alternative brightening agents.

Azelaic Acid

Azelaic acid 20% cream (Azelex, Finacea) emerged as a clinically validated HQ alternative. It inhibits tyrosinase preferentially in hyperactive melanocytes and has a mild anti-inflammatory effect. Critically for women's health, azelaic acid is FDA Pregnancy Category B, meaning animal studies showed no fetal harm and it is considered relatively safe in pregnancy when alternatives are insufficient. This makes it one of the very few topical agents that can be used cautiously to manage melasma during pregnancy and lactation.

Kojic Acid, Arbutin, and Niacinamide

Kojic acid (a fungal metabolite that chelates copper in tyrosinase's active site), arbutin (a glycosylated HQ that releases HQ on hydrolysis), and niacinamide (which inhibits melanosome transfer from melanocytes to keratinocytes) all became commercially significant in this era. None achieved the efficacy of prescription triple combination therapy in head-to-head trials, but they broadened the toolkit for women who could not use HQ or tretinoin, including those pregnant or nursing.

Chemical Peels

Glycolic acid peels (20 to 70%) and salicylic-mandelic acid combinations gained evidence as adjuncts to topical therapy. A 2010 randomized trial in the Journal of Cosmetic Dermatology found that adding glycolic acid peels to HQ therapy significantly improved MASI (Melasma Area and Severity Index) scores compared with HQ alone. Peels carry higher risk of post-inflammatory hyperpigmentation (PIH) in darker skin types, a complication that can worsen the very condition being treated. Women with Fitzpatrick IV through VI skin benefit from lower concentration peels and longer intervals between sessions.

Early Laser and Light Therapy

Q-switched Nd:YAG and intense pulsed light (IPL) devices arrived with initial enthusiasm in the late 1990s. Early results were disappointing in melasma specifically. Unlike post-inflammatory hyperpigmentation or lentigines, melasma involves both epidermal and dermal melanin deposition, and device energy can paradoxically stimulate melanocyte activity, causing rebound darkening. By the early 2000s, most expert guidelines were recommending lasers only as adjuncts to topical treatment, not as primary monotherapy.

The 2010s: Tranexamic Acid, Oral Agents, and a Shift in Understanding

The 2010s produced the most significant mechanistic insight in decades and introduced a genuinely new treatment class.

Tranexamic Acid: From Hemostasis to Pigmentation

Tranexamic acid (TXA) is a lysine analogue traditionally used to control bleeding. A serendipitous observation in Japan in 1979 noted that women receiving oral TXA for heavy menstrual bleeding reported lightening of melasma. The mechanism remained obscure until researchers demonstrated that TXA blocks the interaction between keratinocytes and melanocytes mediated by plasminogen and its activator, reducing prostaglandin-driven melanocyte stimulation. Ultraviolet radiation activates plasminogen in keratinocytes, so TXA interrupts a UV-triggered pathway that conventional tyrosinase inhibitors miss entirely.

A 2017 systematic review and meta-analysis in the Journal of the American Academy of Dermatology, examining 18 studies of oral TXA in melasma, found significant reductions in MASI scores across all included trials, with oral doses of 250 mg twice daily being the most commonly studied regimen. Side effects were generally mild and included gastrointestinal upset. Thrombotic events were rare but cannot be dismissed, particularly in women with additional clotting risk factors.

A useful clinical framework for selecting TXA in women: consider oral TXA for women with hormonally driven melasma who are not pregnant, have no personal or family history of DVT or PE, are not on combined oral contraceptives (which independently raise clotting risk), and have failed or cannot tolerate topical triple combination therapy. Women already on progestogen-only contraception or using non-oral hormonal routes may have a different risk profile and should discuss this explicitly with their prescriber.

Topical Tranexamic Acid

Topical TXA formulations (typically 2 to 5%) avoid systemic thrombotic risk while delivering the same keratinocyte-melanocyte pathway interruption locally. A randomized controlled trial published in the Journal of Dermatological Treatment in 2017 found topical 5% TXA produced MASI reductions comparable to HQ 3% over 12 weeks, with a better tolerability profile. Topical TXA became widely incorporated into melasma protocols, particularly for women who prefer to avoid prescription HQ or who have concerns about systemic exposure.

Cysteamine and Other Emerging Topicals

Cysteamine, an endogenous aminothiol that inhibits tyrosinase and peroxidase activity, reached the melasma literature in this decade. A 2017 double-blind RCT in the British Journal of Dermatology demonstrated that topical cysteamine 5% cream applied for 16 weeks produced significant MASI score reductions compared with placebo, with no significant systemic absorption. Its pregnancy safety data remain limited, and it should not be assumed safe in pregnancy absent direct evidence.

The 2020s: Precision Approaches, the Vascular Hypothesis, and Life-Stage Medicine

Current practice recognizes melasma as more complex than a pure melanocyte disorder.

The Vascular Component

Histological and immunohistochemical studies published from 2016 onward demonstrated that melasma lesions contain significantly increased vascularity, expressed through VEGF (vascular endothelial growth factor) and higher vessel density than surrounding skin. This partly explains why lasers targeting vascular structures (pulsed dye laser, 595 nm) showed unexpected benefit in some series. A 2019 study in the Journal of the European Academy of Dermatology and Venereology found that combination therapy targeting both melanin and vascular components produced greater MASI reductions than melanin-only approaches.

Low-Fluence Q-Switched Nd:YAG (the "Toning" Protocol)

Multiple passes at low fluence with Q-switched 1064 nm Nd:YAG became widely used in East and Southeast Asian dermatology practices. Results in controlled trials are mixed. The risk of PIH remains real in darker skin. Current American Academy of Dermatology and Melasma Study Group guidance reserves energy-based devices as third-line options after optimized topical therapy with consistent sun protection has been tried for at least 3 to 6 months.

Microneedling as a Drug-Delivery Tool

Microneedling with radiofrequency or combined with topical TXA or vitamin C improved delivery of actives into the dermis in recent small trials. Evidence remains preliminary (no large RCTs), so it should be viewed as adjunctive rather than primary therapy.

Female Hormonal Status Remains the Central Variable

A point that the full treatment history underlines: every intervention works better when the hormonal trigger is addressed. Women who continue on estrogen-containing oral contraceptives while applying triple combination cream have significantly higher relapse rates than those who switch to non-estrogen contraception. Women entering perimenopause who start systemic HRT and notice new or worsening melasma may benefit from transdermal rather than oral estrogen routes, which produce lower peak estradiol levels in skin. The Menopause Society (formerly NAMS) notes that transdermal estrogen has a different metabolic profile than oral estrogen, though direct trial data on melasma recurrence with transdermal vs. Oral HRT are lacking.

Hormonal Triggers Across the Female Life Span

Melasma is not one static condition. It presents differently depending on where you are hormonally.

Reproductive Years and Oral Contraceptives

Oral contraceptive-associated melasma typically appears 1 to 3 months after starting combined OCP use. Prevalence in OCP users is estimated at 10 to 25%. Switching to progestogen-only pills, the hormonal IUD (levonorgestrel IUS), or non-hormonal contraception often slows progression, though existing pigmentation rarely disappears without topical treatment.

Pregnancy (Chloasma Gravidarum)

Melasma affects approximately 50 to 70% of pregnant women, typically emerging in the second trimester when estrogen and progesterone levels peak. The mask-of-pregnancy pattern (centrofacial, malar, or mandibular) is driven by elevated MSH, estrogen, and progesterone acting on sensitized melanocytes. Most cases improve postpartum, though a significant minority persist, particularly in women who immediately start hormonal contraception after delivery.

During pregnancy: most depigmenting agents are contraindicated. Hydroquinone has measurable systemic absorption and no established fetal safety data. Tretinoin carries a known teratogenicity signal in animal models and should be avoided entirely in pregnancy. Kojic acid and chemical peels lack adequate pregnancy safety data. The only topical options with any support for cautious use are azelaic acid (Pregnancy Category B) and physical sunscreen (mineral zinc oxide or titanium dioxide). Oral TXA is not recommended in pregnancy given its anticoagulant-pathway mechanism and limited safety data.

Postpartum and Lactation

After delivery, postpartum melasma often fades over 3 to 6 months, especially with consistent sun avoidance. Women who are breastfeeding face similar restrictions to pregnancy: tretinoin and HQ are not recommended during lactation given unknown transfer risk. Azelaic acid is considered acceptable. Women may begin broader topical therapy once they have weaned.

PCOS

Polycystic ovary syndrome is associated with elevated androgen levels and, in some phenotypes, insulin resistance that alters skin biology. PCOS is also associated with higher rates of melasma, likely through combined effects of elevated estrogen exposure and chronic inflammation. Women with PCOS who are prescribed oral contraceptives for cycle regulation may develop melasma on this basis. Addressing insulin resistance with metformin or lifestyle change does not directly treat melasma, but reducing the hormonal milieu driving it may help sustain topical treatment results.

Perimenopause and Menopause

Perimenopause introduces fluctuating and often elevated early estrogen levels before the eventual decline. New melasma in a woman aged 42 to 52 may reflect these fluctuations. Women starting systemic HRT for vasomotor symptoms who notice new melasma should discuss route of delivery with their clinician. Topical vaginal estrogen for genitourinary syndrome of menopause (GSM) has negligible systemic absorption and is not meaningfully associated with melasma.

Who This Treatment History Applies to: Right Fit and Not Right Fit

Not every option is right at every life stage.

Well-suited for triple combination topical therapy:

• Non-pregnant women in reproductive years with OCP-related or sun-driven melasma
• Women postpartum and not breastfeeding
• Perimenopausal women not on systemic HRT

Better suited to azelaic acid and mineral sunscreen only:

• Pregnant women at any trimester
• Women actively breastfeeding
• Women with a history of significant HQ-associated ochronosis

Candidates for oral tranexamic acid 250 mg twice daily:

• Non-pregnant women with recurrent or refractory melasma
• Women NOT using combined oral contraceptives concurrently (due to additive clotting risk)
• Women with no personal or family history of thromboembolism

Candidates for device-based adjuncts (IPL, low-fluence QSNY, pulsed dye):

• Women with Fitzpatrick I through III skin who have optimized topical therapy for at least 3 to 6 months without adequate response
• Should be approached with caution in Fitzpatrick IV through VI given PIH risk

Pregnancy and Lactation: Safety Table

This section covers drug safety directly, because the data are genuinely thin and the defaults are restrictive.

| Agent | Pregnancy | Lactation | |---|---|---| | Hydroquinone 4% | Avoid: systemic absorption documented, no human safety data | Avoid: unknown transfer; insufficient data | | Tretinoin 0.025-0.1% | Contraindicated: teratogenic in animal models | Avoid: limited human data | | Triple combination cream (Tri-Luma) | Contraindicated: contains tretinoin | Avoid | | Azelaic acid 15-20% | Cautious use acceptable (FDA Pregnancy Category B) | Considered low risk; limited transfer data | | Tranexamic acid oral | Avoid: insufficient pregnancy safety data; anticoagulant mechanism | Not recommended | | Topical tranexamic acid 2-5% | Insufficient data; best avoided | Insufficient data | | Kojic acid | Insufficient data; avoid | Insufficient data | | Mineral sunscreen (zinc oxide, titanium dioxide) | Safe; recommended daily | Safe | | Chemical peels (glycolic acid) | Avoid: systemic salicylate absorption risk with higher concentrations | Avoid salicylic acid peels; glycolic at low concentrations likely low risk |

FAQ